主要从事肿瘤生物学研究，曾发现DNA损伤反应防止肿瘤发生的新机制（PNAS，第一作者，2009年）。近年来在肿瘤耐药机制方面研究取得重要进展：发现乳腺癌内分泌治疗耐药的新机制，阐释了乳腺癌耐药的分子调控过程（Nature Medicine，第一作者，2011年），是该领域国际上重要进展（Faculty of 1000：2011年7月国际肿瘤生物学领域七大进展之一）。此外，通过建立MCU敲除小鼠模型，发现线粒体钙异常导致机体代谢紊乱，与肿瘤发生密切相关（Nature Cell Biology，第一作者，2013年）。共发表SCI论文16篇，总影响因子161，累计被引近600次。目前担任973课题组长，并主持国际科技合作专项课题，主要研究代谢异常导致肿瘤发生的分子机制。

The applicant has been working on the cancer biology for many years. He found a new mechanism of how DNA damage response prevents tumorigenesis (Pan et al., PNAS, 2009). Recently, he discovered a new molecular mechanism of the resistance to endocrine therapy in breast cancer. He elucidated the related signal pathway and its regulation as well (Pan et al., Nature Medicine, 2011). This finding was known as one of top 7 progress in cancer biology field in July 2011 by Faculty of 1000. He also generated a mitochondrial calcium uniporter knockout mouse and found that the defect in mitochondrial calcium led to the dysfunction in metabolism, which is closely relevant to cancer development (Pan et al., Nature Cell Biology, 2013). He has published 16 SCI papers, the total impact factor of which is 161. His publications have been cited near 600 times totally. As a project leader, he’s been funded by National Basic Research Program of China (973) and the International Scientific and Technological Cooperation projects, mainly focusing on the mechanism of how dysregulation of metabolism leads to cancer.